Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPaola MinettoCNClara NurraMCMichele Cea

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no impact of DNMT3A mutations on outcomes in NPM1 mutant AML treated with idarubicin, suggesting effective early responses are key.

Key Points

  • Remission rates were unaffected by DNMT3A mutations in NPM1 mutant acute myeloid leukemia patients treated with idarubicin.
  • Among 53 patients, 83% achieved molecular MRD negativity after treatment, strongly linked to improved overall survival outcomes.
  • Retrospective analysis employed next-generation sequencing on bone marrow samples to evaluate mutation impacts on prognosis.
  • Findings highlight that effective early molecular responses, rather than adverse mutations, may drive long-term survival in AML patients.

Cite This Study

Minetto et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e456https://doi.org/10.1182/blood-2025-1625
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic covariates associated with outcomes in patients with <i>NPM1</i>-mutated acute myeloid leukemia2025 · 3 citations
  2. 2Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  3. 3Prognostic Value of Molecular and Clinical Features in Patients with NPM1 Gene Mutation in Acute Myeloid Leukemia2025 · 1 citations
  4. 4Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations
  5. 5DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors2025 · 2 citations